Athenex, Inc. (56) | Intellectual Property (14)
Browse by Subcategory
Recent Contracts
-
Third Supplemental Agreement and Amendment to License Agreement by and among Athenex, Inc. and Chongqinq Guangzhou Xiangxue Pharmaceutical Co., Ltd., dated November 8, 2021
(Filed With SEC on March 16, 2022)
-
First Supplemental Agreement to License Agreement by and among Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd. and Guangzhou Xiangxue Pharmaceutical Co., Ltd., dated...
(Filed With SEC on March 16, 2022)
-
Second Amended and Restated Exclusive License and Option Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated October 12, 2021
(Filed With SEC on March 16, 2022)
-
Amended and Restated Exclusive License and Option Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated February 28, 2020
(Filed With SEC on August 5, 2021)
-
Second Amendment to License Agreement dated as of February 15, 2021 by and between Athenex, Inc. and PharmaEssentia Corp
(Filed With SEC on May 6, 2021)
-
Second Supplemental Agreement to License Agreement dated December 12, 2019 by and among Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd. and Guangzhou Xiangxue...
(Filed With SEC on August 6, 2020)
-
License Agreement by and between Kinex Pharmaceuticals, Inc. and PharmaEssentia Corp., effective as of December 16, 2013
(Filed With SEC on May 7, 2020)
-
Second Amendment to License Agreement by and between Athenex, Inc. and PharmaEssentia Corp., effective as of November 27, 2018
(Filed With SEC on May 7, 2020)
-
License Agreement by and between Kinex Pharmaceuticals, LLC and Guangzhou Xiangxue New Drug Discovery and Development Company Limited, effective as of May 6, 2012
(Filed With SEC on May 7, 2020)
-
License Agreement between the Company and Guangzhou Xiangxue Pharmaceutical Co., Ltd. dated December 12, 2019
(Filed With SEC on December 16, 2019)
-
Second Amendment to License and Development Agreement by and between Athenex, Inc., Almirall, S.A., and Aqua Pharmaceuticals LLC, dated as of June 18, 2019
(Filed With SEC on August 7, 2019)
-
Fifth Amendment to License Agreement by and between Athenex, Inc. and Hanmi Pharmaceutical Co. Ltd., effective as of September 4, 2018
(Filed With SEC on March 11, 2019)
-
Second Amendment to License Agreement by and between Athenex, Inc. and PharmaEssentia Corp., effective as of November 27, 2018
(Filed With SEC on March 11, 2019)
-
License Agreement, dated as of December 30, 2018 by and between Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd
(Filed With SEC on January 3, 2019)